Aviva’s Protolabs PRLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-40,188
Closed -$1.03M 1029
2022
Q4
$1.03M Sell
40,188
-1,114
-3% -$33.1K 0.01% 798
2022
Q3
$1.5M Sell
41,302
-1,179
-3% -$51.1K 0.01% 791
2022
Q2
$2.03M Buy
42,481
+219
+0.5% +$10.2K 0.01% 801
2022
Q1
$2.24M Sell
42,262
-2,639
-6% -$139K 0.01% 797
2021
Q4
$2.31M Buy
44,901
+22,881
+104% +$1.35M 0.01% 840
2021
Q3
$1.47M Buy
+22,020
New +$1.72M 0.01% 896
2021
Q1
Sell
-9,406
Closed -$1.44M 973
2020
Q4
$1.44M Sell
9,406
-7,626
-45% -$1.08M 0.01% 779
2020
Q3
$2.21M Sell
17,032
-2,918
-15% -$384K 0.01% 748
2020
Q2
$2.24M Sell
19,950
-28,616
-59% -$2.94M 0.01% 740
2020
Q1
$3.7M Buy
48,566
+28,813
+146% +$2.67M 0.03% 538
2019
Q4
$2.01M Buy
+19,753
New +$1.96M 0.01% 709

Other funds holding PRLB

Aviva's PRLB Position: Q1 2023 in Review

Aviva sold out of Protolabs (PRLB) in Q1 2023, closing a stake of 40,188 shares — an estimated $1.03M sold.

Aviva first reported a position in PRLB in Q4 2019 and held it in 11 quarters. The position peaked at $3.7M in Q1 2020. 198 funds tracked by Wall St. Rank hold PRLB as of Q1 2023.

  • Aviva reported no remaining Protolabs position as of Q1 2023 after selling out during the quarter.
  • Aviva sold 40,188 Protolabs shares in Q1 2023, an estimated $1.03M.
  • Aviva first reported a position in Protolabs in Q4 2019 and held it in 11 quarters.
  • Aviva's Protolabs position peaked at $3.7M in Q1 2020.
  • 198 funds tracked by Wall St. Rank held Protolabs as of Q1 2023.

Based on Aviva's 13F filing for Q1 2023, filed 12 May 2023.